| Literature DB >> 33283100 |
Zheng Li1,2, Hongwei Chen2, Huixia Zhang2, Yan Li2, Caiyun Wang2, Liping Bai2,3, Wei Zhang2,3, Zhihong Jiang2,3.
Abstract
The pathogenesis similarity is leading to the introduction of drugs commonly used in rheumatoid arthritis (RA) into coronavirus disease (COVID-19) treatment. Traditional Chinese medicine (TCM) was widely used for the treatment of infectious diseases and rheumatic diseases. However, there is little knowledge of the relationship between COVID-19 and RA treatment employing TCM formulas. The present work was aimed to compare the similarity and specificity of TCM formulas for the management of COVID-19 and RA, as well as to deduce the potential mechanism of TCM for COVID-19 treatment. Two formulas including lianhuaqingwen (LHQW) and duhuojisheng (DHJS) were selected as the representatives of TCM for COVID-19 and RA treatment, respectively. An integrated network pharmacology was used to investigate their similarity and specificity. Although different herbs are present in the two formulas, they generated fairly similar ingredients, targets, interaction networks and enriched pathways, which were mainly involved in virus infection, inflammation, and immune dysregulation. Undoubtedly, they also exhibited their respective specificity. LHQW showed the cold property and lung channel tropism which dominated heat-clearing and lung-freeing, while DHJS showed the warm property and liver channel tropism. Herbal compatibility of LHQW was more in line with the rules of the TCM formula against coronavirus disease. Although both formulas suggested multifunctionality in virus infection and inflammation, LHQW was inclined to cope with virus infection, while DHJS was inclined to cope with inflammation. Therefore, LHQW was reliable for providing the desired efficacy in COVID-19 management because of its cold property, lung channel tropism, and multifunctionality for coping with virus infection and inflammation.Entities:
Year: 2020 PMID: 33283100 PMCID: PMC7711705 DOI: 10.1021/acsomega.0c04377
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Workflow of the current study.
Herbal Composition with the Property, Flavor, and Channel Tropism of LHQW and DHJS
| formula | no. | herb name (Chinese) | property and flavor | channel tropism |
|---|---|---|---|---|
| LHQW | 1 | slightly cold, bitter | lung, heart | |
| 2 | cold, sweet | lung, stomach | ||
| 3 | warm, pungent | lung, bladder | ||
| 4 | slightly warm, bitter | lung, large intestine | ||
| 5 | cold, bitter | heart, stomach | ||
| 6 | slightly cold, bitter | liver, stomach | ||
| 7 | slightly cold, pungent | lung | ||
| 8 | slightly warm, pungent | spleen, stomach | ||
| 9 | natured, sweet, | lung, heart | ||
| 10 | natured, sweet, | heart, lung | ||
| 11 | cold, bitter | spleen, stomach | ||
| 12 | cold, pungent | lung, stomach | ||
| 13 | cold, pungent | lung | ||
| DHJS | 1 | slightly warm, pungent | kidney, bladder | |
| 2 | natured, bitter | liver, kidney | ||
| 3 | natured, pungent, | stomach, liver | ||
| 4 | slightly warm, pungent | bladder, liver | ||
| 5 | warm, pungent | heart, lung | ||
| 6 | warm, sweet | liver, heart | ||
| 7 | slightly cold, bitter | liver, spleen | ||
| 8 | warm, pungent | liver, gallbladder | ||
| 9 | slightly warm, sweet | liver, kidney | ||
| 10 | warm, sweet | liver, kidney | ||
| 11 | natured, bitter | liver, kidney | ||
| 12 | natured, sweet | spleen, lung | ||
| 13 | natured, sweet | heart, lung | ||
| 14 | natured, sweet | heart, lung | ||
| 15 | hot, pungent | kidney, spleen |
Figure 2Main function and channel tropism of LHQW and DHJS based on TCM theory.
Figure 3Chemical ingredients and putative targets of LHQW and DHJS. (A) Venn diagram of candidate ingredients; (B) top 10 ingredients from LHQW and DHJS; (C) Venn diagram of putative targets; and (D) top 25 targets from LHQW and DHJS. For panels B and D, items labeled with red color were shared by LHQW and DHJS.
Figure 4Integration analysis of drug targets and disease targets. (A) Target intersection of LHQW-coronavirus, DHJS-coronavirus, and LHQW-DHJS-coronavirus; (B) mapping and contribution of each herb in LHQW to the target integration of LHQW-coronavirus; (C) mapping and contribution of each herb in DHJS to the target integration of DHJS-coronavirus; (D) scores scatter 3D plot generated from PCA using the target profile data of drugs and disease; and (E) heatmap combined with HCA using the target profile data of drugs and disease.
Figure 5Comparison of drug–disease target interaction. (A) LHQW-ingredient-target-disease interaction network; (B) DHJS-ingredient-target-disease interaction network; (C) herbal affiliation of the top 20 ingredients in LHQW; and (D) herbal affiliation of the top 20 ingredients in DHJS.
Figure 6Merged PPI network of LHQW and DHJS. The left large part of the PPI network belonged to DHJS, while the entire PPI network belonged to LHQW except APOD and IRF3.
Figure 7GO and KEGG enrichment. Top 10 GO entries of LHQW (A) and DHJS (B); top 10 KEGG pathways of LHQW (C) and DHJS (D); (E) representative KEGG pathway of LHQW rebuilt from the enriched KEGG graph; and (F) LHQW and DHJS shared extensive pathways involved in the pathogenesis and therapeutic of COVID-19, other virus diseases, and RA. For panels A, B, C, and D, items with an orange background were shared by LHQW and DHJS.
Figure 8Deduced signaling network to decipher the mechanism of the LHQW formula for COVID-19 management.